BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NextGen Sciences Ltd. to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceutical Co. Ltd. (TKDG.DE)


2/2/2010 12:51:20 PM

Ann Arbor, MI, February 2nd 2010 - NextGen Sciences, a leading provider of biomarker discovery, assay development, validation and testing services, and Takeda Pharmaceutical Company Limited (“Takeda”) have entered into an agreement under which NextGen Sciences will develop validated protein biomarker assays to be used in Takeda’s preclinical and clinical studies to support their drive towards personalized medicine.

The biomarker assays will be designed to target specific protein isoforms found in liver and muscle in multiple species, for use in preclinical studies, and will also be validated for use in clinical studies. NextGen Sciences’ Multiple Reaction Monitoring (MRM) protein assay platform is ideal for studies of this kind, which involve multiple isoforms and multiple species.

Dr Michael Pisano, CEO of NextGen Sciences, commented: “We are delighted to have been chosen for this project and look forward to working closely with Takeda’s scientists in Japan.”

NextGen Sciences, a wholly owned subsidiary of NextGen Group PLC

NextGen Group PLC (AIM: NGG) is a provider of biomarker services for pharmaceutical and biotech companies globally. Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients.

Headquartered in Ann Arbor, Michigan, NextGen Sciences’ range of services, which include biomarker discovery, assay development, validation and testing are employed by its customers as a key part of the biomarker-based drug and diagnostic development process.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES